ES2177554T3 - Glicoproteinas bifuncionales con un complemento de carbohidrato modificado, y su uso en la terapia selectiva de tumores. - Google Patents

Glicoproteinas bifuncionales con un complemento de carbohidrato modificado, y su uso en la terapia selectiva de tumores.

Info

Publication number
ES2177554T3
ES2177554T3 ES94106394T ES94106394T ES2177554T3 ES 2177554 T3 ES2177554 T3 ES 2177554T3 ES 94106394 T ES94106394 T ES 94106394T ES 94106394 T ES94106394 T ES 94106394T ES 2177554 T3 ES2177554 T3 ES 2177554T3
Authority
ES
Spain
Prior art keywords
glicoproteins
complement
bifunctional
carbohydrate
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94106394T
Other languages
English (en)
Inventor
Klaus Dr Bosslet
Jorg Dr Czech
Dieter Dr Hoffmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis Deutschland GmbH
Original Assignee
Aventis Pharma Deutschland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Deutschland GmbH filed Critical Aventis Pharma Deutschland GmbH
Application granted granted Critical
Publication of ES2177554T3 publication Critical patent/ES2177554T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0002—Antibodies with enzymatic activity, e.g. abzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/61—Fusion polypeptide containing an enzyme fusion for detection (lacZ, luciferase)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Steroid Compounds (AREA)

Abstract

SON EN ESTO PROVISTOS LAS GLICOPROTEINAS BIFUNCIONALES MODIFICADAS DE COMPLEMENTO DE CARBOHIDRATO, Y SU USO EN TERAPIA DE TUMORSELECTIVO. LAS GLICOPROTEINAS BIFUNCIONALES COMPRENDEN UN PRIMER COMPONENTE QUE SE UNE ESPECIFICAMENTE A UN ANTIGENO ESPECIFICO DE TUMOR Y UN SEGUNDO COMPONENTE QUE TIENE ACTIVIDAD ENZIMATICA POR MEDIO DEL CUAL UNA PREDROGA ES ESCINDIDA EN UNA DROGA CITOTOXICA. EL COMPLEMENTO DE CARBOHIDRATO COMPRENDE AL MENOS UN RESIDUO DE CARBOHIDRATO SELECCIONADO DEL GRUPO QUE CONSTA DE MANOSA, GALACTOSA, N-ACETILGLUCOSAMINA, N-ACETILLACTOSA, GLUCOSA Y FUCOSA. EL COMPLEMENTO DE CARBOHIDRATO MODIFICADO CONTRIBUYE A LA CONCENTRACION RELATIVA INCREMENTADA DE LAS GLICOPROTEINAS A LOS LUGARES DEL TUMOR, Y EL ESPACIO LIBRE INCREMENTADO DE LA CIRCULACION GENERAL Y LOS LUGARES DE NO TUMOR.
ES94106394T 1993-05-04 1994-04-25 Glicoproteinas bifuncionales con un complemento de carbohidrato modificado, y su uso en la terapia selectiva de tumores. Expired - Lifetime ES2177554T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4314556A DE4314556A1 (de) 1993-05-04 1993-05-04 Modifizierte Antikörperenzymkonjugate und Fusionsproteine sowie ihre Anwendung zur tumorselektiven Therapie

Publications (1)

Publication Number Publication Date
ES2177554T3 true ES2177554T3 (es) 2002-12-16

Family

ID=6487030

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94106394T Expired - Lifetime ES2177554T3 (es) 1993-05-04 1994-04-25 Glicoproteinas bifuncionales con un complemento de carbohidrato modificado, y su uso en la terapia selectiva de tumores.

Country Status (11)

Country Link
US (1) US8552159B2 (es)
EP (1) EP0623352B1 (es)
JP (1) JPH06319554A (es)
KR (1) KR100387452B1 (es)
AT (1) ATE220921T1 (es)
AU (1) AU684750B2 (es)
CA (1) CA2122745C (es)
DE (2) DE4314556A1 (es)
DK (1) DK0623352T3 (es)
ES (1) ES2177554T3 (es)
PT (1) PT623352E (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19513676A1 (de) * 1995-04-11 1996-10-17 Behringwerke Ag Cytoplasmatische Expression von Antikörpern, Antikörperfragmenten und Antikörperfragmentfusionsmolekülen in E.coli
EP0795334B1 (de) * 1996-03-12 2006-02-01 Sanofi-Aventis Deutschland GmbH Neuartige Prodrugs für die Therapie von Tumoren und entzündlichen Erkrankungen
CA2704600C (en) 1999-04-09 2016-10-25 Kyowa Kirin Co., Ltd. A method for producing antibodies with increased adcc activity
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
EP1500400A4 (en) 2002-04-09 2006-10-11 Kyowa Hakko Kogyo Kk MEDICAMENT WITH ANTIBODY COMPOSITION
US7691810B2 (en) 2003-10-09 2010-04-06 Kyowa Hakko Kirin Co., Ltd Method of producing recombinant antithrombin III composition
KR101540319B1 (ko) * 2013-10-01 2015-07-30 한국생명공학연구원 cyb5R3 유전자 또는 단백질을 유효성분으로 포함하는 암 예방 및 치료용 약학적 조성물
BR112020013244A2 (pt) * 2018-01-04 2020-12-01 Shanghai Lumosa Therapeutics Co., Ltd. proteínas de fusão de anticorpo citosina-desaminase de domínio único

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4859449A (en) * 1987-09-14 1989-08-22 Center For Molecular Medicine And Immunology Modified antibodies for enhanced hepatocyte clearance
GB8809616D0 (en) * 1988-04-22 1988-05-25 Cancer Res Campaign Tech Further improvements relating to drug delivery systems
US5632990A (en) * 1988-04-22 1997-05-27 Cancer Research Campaign Tech. Ltd. Treatment for tumors comprising conjugated antibody A5B7 and a prodrug
US5135736A (en) * 1988-08-15 1992-08-04 Neorx Corporation Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
GB8905669D0 (en) * 1989-03-13 1989-04-26 Celltech Ltd Modified antibodies
DE4106389A1 (de) * 1991-02-28 1992-09-03 Behringwerke Ag Fusionsproteine zur prodrug-aktivierung, ihre herstellung und verwendung
GB9022543D0 (en) * 1990-10-17 1990-11-28 Wellcome Found Antibody production
AU656181B2 (en) * 1991-05-03 1995-01-27 Pasteur Sanofi Diagnostics Heterobifunctional antibodies possessing dual catalytic and specific antigen binding properties and methods using them
DE4233152A1 (de) * 1992-10-02 1994-04-07 Behringwerke Ag Antikörper-Enzym-Konjugate zur Prodrug-Aktivierung

Also Published As

Publication number Publication date
ATE220921T1 (de) 2002-08-15
US8552159B2 (en) 2013-10-08
DE69431018T2 (de) 2003-02-27
CA2122745C (en) 2010-06-22
DE4314556A1 (de) 1994-11-10
KR100387452B1 (ko) 2003-11-13
US20040202646A1 (en) 2004-10-14
PT623352E (pt) 2002-12-31
DK0623352T3 (da) 2002-11-11
EP0623352A3 (en) 1995-02-22
CA2122745A1 (en) 1994-11-05
EP0623352A2 (en) 1994-11-09
AU6182994A (en) 1994-11-10
JPH06319554A (ja) 1994-11-22
EP0623352B1 (en) 2002-07-24
DE69431018D1 (de) 2002-08-29
AU684750B2 (en) 1998-01-08

Similar Documents

Publication Publication Date Title
DE69535999D1 (de) Verfahren und zusammensetzungen für erhöhte tumorzell-immunität in vivo
BR9809791A (pt) Compostos de fosfato de aminoalquil glucosamina e seu uso como auxiliares e imuno efetores
ES2086997T3 (es) Oligonucleotido-alquilfosfonatos y -alquilfosfonotioatos.
IT1107478B (it) Perfezionamento nei sistemi per la introduzione di sostanze fluide o semi-solide come plasma soluzioni di glucosio o simili in pazienti
ES2177554T3 (es) Glicoproteinas bifuncionales con un complemento de carbohidrato modificado, y su uso en la terapia selectiva de tumores.
ES2191018T3 (es) Procedimiento para detectar micrometastasis de cancer de prostata.
ES2153034T3 (es) Sistema de suministro en microparticulas.
DE60038104D1 (de) Arzneimittelzubereitungen für die behandlung von alpha-galactosidase a-mangel
CY1105364T1 (el) Μεθοδοι και συνθεσεις διαμορφωσης ανοσοποιησης
ES2029263T3 (es) Soporte de montaje.
AR033093A1 (es) Articulo absorbente con alas desprendibles
EP0969720A4 (en) COMBINED TUMOR SUPPRESSOR GENE THERAPY AND CHEMOTHERAPY IN NEOPLASM TREATMENT
ES2147216T3 (es) Bisconjugados que comprenden dos sacaridos y un grupo de union.
ES2104598T3 (es) Uso del cofactor ii de heparina modificado.
ES2157290T3 (es) Esteroides con un grupo 17-espirometilen lactona o lactol.
MX9303709A (es) Nucleosidos de purina substituidos e intermediarios de los mismos, que tienen actividad anti-viral y anti-cancerigena y composicion farmaceutica que los contiene.
MX9804459A (es) Procedimiento para el diagnostico y terapia de epitelioma.
ES2046699T3 (es) Un conjunto de panel.
SE9701118L (sv) Vägräcke
DE3767287D1 (de) Potenzierung von prazosin.
ES2100051T3 (es) Sintesis de bloques dimeros y su uso en el ensamblaje de oligonucleotidos.
DE69905392D1 (de) Verwendung von einer pharmazeutischen zusammensetzung enthaltende ein antikrebs mittel und mindestens ein peptid
ES2091813T3 (es) Colorantes en dispersion.
ATE235888T1 (de) Lyophilisiertes thioxanthenon-antitumormedikament
ES2130607T3 (es) Ablandamiento de cuero.